| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: =98.33%
| Targets |
Laminin receptor; Laminin (925-933) targets the laminin receptor, binding to it at a concentration of 1 mg/mL. This peptide corresponds to the cell-binding active site on the laminin B1 chain, acting by mimicking the active domain of full-length laminin. It exhibits different modulatory effects on laminin-induced cellular activities across cell types: acting as a laminin agonist in human SK HEP-1 cells and as a partial antagonist in embryonic chick endothelial cells.
|
|---|---|
| ln Vitro |
Laminin, murine epidermal growth factor (mEGF), and the synthetic laminin peptide Lam.B1(925-933) (a linear peptide from the B1 chain of murine laminin, CDPGY1GSR-amide) all stimulate endothelial cell motility above basal rates, whereas a synthetic mEGF fragment, mEGF33-42 (a linear peptide from the C-loop of mEGF, acetyl-C-[S-Acm]-VIGYSGDR-C-[S-Acm]-amide), inhibits motility. In both human SK HEP-1 and embryonic chick endothelial cells, mEGF33-42 blocks both EGF- and laminin-stimulated locomotion of endothelial cells [1].
In in vitro cell studies, Laminin (925-933) at concentrations of 100 and 300 μg/mL stimulates the attachment of HT-1080 human fibrosarcoma cells and CHO Chinese hamster ovary cells to culture plates. In B16/F10 murine melanoma cells, this peptide induces chemotaxis while inhibiting chemotaxis induced by full-length laminin, but does not affect fibronectin-induced chemotaxis. When conjugated to an agarose hydrogel backbone, Laminin (925-933) enhances neurite outgrowth in isolated chick embryo dorsal root ganglia and PC12 cells. This peptide exhibits an additive effect when co-incubated with laminin or EGF. |
| ln Vivo |
In vivo, mEGF33-42 also blocks both laminin- and mEGF-induced angiogenesis in the chick. In the human cell line. Lam.B1(925-933) has an additive effect in coincubation with either laminin or mEGF, but it blocks their effects in the chick cells. Lam.B1(925-933) alone stimulates angiogenesis in the chick but blocks laminin-induced angiogenesis. Thus, mEGF33-42 acts as a general laminin antagonist, whereas Lam.B1(925-933) acts as a laminin agonist in human cells, but in chick cells it acts as a partial antagonist. We propose that the presence of an anionic group at the eighth residue of mEGF33-42 may be the source of the antagonistic effects seen with this peptide as compared with the laminin fragment. These findings have important implications in the design of human antiangiogenic agents, and also in the use of chick models in the study of human disease [1].
In in vivo chick embryo studies, Laminin (925-933) alone stimulates angiogenesis but blocks laminin-induced angiogenesis. In in vivo animal studies, Laminin (925-933)-derivatized gels enhance nerve regeneration in a transected rat dorsal root model compared to underivatized gels. |
| Cell Assay |
Cell Adhesion Assay: HT-1080 or CHO cells are seeded onto culture plates coated with Laminin (925-933) peptide at concentrations of 100 or 300 μg/mL. After incubation at 37°C for a defined period, non-adherent cells are removed by washing, and adherent cells are counted or stained for evaluation.
Chemotaxis Assay: In Boyden chambers, B16/F10 murine melanoma cells are incubated with Laminin (925-933), and cell migration through filter membranes is quantified to evaluate the peptide's effect on chemotaxis. Neurite Outgrowth Assay: Laminin (925-933) conjugated to an agarose hydrogel backbone is used as a three-dimensional substrate. Chick embryo dorsal root ganglia or PC12 cells are seeded into this matrix, and neurite length is measured by microscopy to assess neurite-promoting effects. |
| Animal Protocol |
Chick Angiogenesis Assay: In the chick chorioallantoic membrane model, Laminin (925-933) is applied alone or in combination with laminin. Angiogenesis is assessed by counting vascular branch points or measuring vessel density.
Rat Nerve Regeneration Assay: In a transected rat dorsal root model, Laminin (925-933)-derivatized hydrogels are implanted. Nerve regeneration is evaluated by histology and functional assessment, comparing with underivatized gels, laminin gels, and saline-filled nerve guidance channels. |
| ADME/Pharmacokinetics |
Laminin (925-933)(TFA) has a molecular weight of 1081.08 g/mol, a molecular formula of C₄₂H₆₃F₃N₁₂O₁₆S, and the amino acid sequence CDPGYIGSR. Water solubility: 30 mg/mL. Storage conditions: Powder should be stored at -20°C in a dry, sealed container. Once prepared, stock solutions should be stored in tightly sealed vials and used within 1 month, avoiding repeated freeze-thaw cycles.
|
| Toxicity/Toxicokinetics |
According to the Safety Data Sheet, Laminin (925-933)(TFA) is classified as a non-hazardous substance or mixture with no GHS hazard label elements. Regarding carcinogenicity, it is not listed as hazardous by NTP, IARC, OSHA, or ACGIH. The detailed toxicological effects of this product have not been thoroughly studied. This product is for non-human research use only and is not intended for diagnostic, therapeutic, or veterinary use.
|
| References | |
| Additional Infomation |
The free base form of Laminin (925-933)(TFA) has the CAS number 110590-60-8, while the TFA salt form has the CAS number 2828432-44-4. YIGSR is the core active sequence within this peptide fragment, and this sequence has been shown to promote the adhesion of various epithelial cells and possesses the potential to inhibit angiogenesis and solid tumor growth.
|
| Molecular Formula |
C42H63F3N12O16S
|
|---|---|
| Molecular Weight |
1081.08
|
| Exact Mass |
1080.415
|
| CAS # |
2828432-44-4
|
| Related CAS # |
Laminin (925-933);110590-60-8
|
| PubChem CID |
138454860
|
| Sequence |
Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg
H-Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg-OH.TFA; Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg
|
| SequenceShortening |
CDPGYIGSR
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
74
|
| Complexity |
1860
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C(N1CCC[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)O)CCCNC(N)=N)CC1C=CC(O)=CC=1)(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CS.C(F)(F)(F)C(=O)O
|
| InChi Key |
KCSGEDZIDRWIQM-XBWDXPLKSA-N
|
| InChi Code |
InChI=1S/C40H62N12O14S.C2HF3O2/c1-3-20(2)32(37(63)46-17-30(56)48-27(18-53)35(61)49-24(39(65)66)6-4-12-44-40(42)43)51-34(60)25(14-21-8-10-22(54)11-9-21)47-29(55)16-45-36(62)28-7-5-13-52(28)38(64)26(15-31(57)58)50-33(59)23(41)19-67;3-2(4,5)1(6)7/h8-11,20,23-28,32,53-54,67H,3-7,12-19,41H2,1-2H3,(H,45,62)(H,46,63)(H,47,55)(H,48,56)(H,49,61)(H,50,59)(H,51,60)(H,57,58)(H,65,66)(H4,42,43,44);(H,6,7)/t20-,23-,24-,25-,26-,27-,28-,32-;/m0./s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid;2,2,2-trifluoroacetic acid
|
| Synonyms |
Laminin (925-933)(TFA); 2828432-44-4; (2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid;2,2,2-trifluoroacetic acid; Laminin (925-933) TFA;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (46.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (46.25 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9250 mL | 4.6250 mL | 9.2500 mL | |
| 5 mM | 0.1850 mL | 0.9250 mL | 1.8500 mL | |
| 10 mM | 0.0925 mL | 0.4625 mL | 0.9250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA